The Fresubin 2 kcal DRINK. Compact high-calorie nutrition for fragile patients

Fresubin 2 kcal DRINK sits cold on the bedside table, a small 200 ml bottle that smells faintly of vanilla when the cap clicks open. For many hospital patients this concentrated sip from Fresenius Kabi is the difference between losing and stabilizing weight.

What Fresubin 2 kcal DRINK actually is

Fresubin 2 kcal DRINK is a ready-to-use, high-energy oral nutritional supplement that provides 2 kilocalories per milliliter, meaning 400 kilocalories in a 200 ml bottle. It is produced by Fresenius Kabi, the clinical nutrition specialist of Fresenius SE & Co. KGaA. The product is designed for people who cannot cover their energy and nutrient needs with normal food, including older patients and those with chronic disease.

According to the official product information, Fresubin 2 kcal DRINK is nutritionally complete, containing proteins, fats, carbohydrates, vitamins and trace elements in a balanced formulation. It is recommended as a food for special medical purposes and must be used under medical supervision, a detail that dietitian Dr. Andrea Farke at Fresenius Kabi repeatedly stresses in professional presentations.

Nutritional profile and indications

The energy density of 2 kcal/ml allows clinicians to deliver substantial calories in a small volume, which is crucial for patients with early satiety, swallowing difficulties or fluid restrictions. Fresubin 2 kcal DRINK typically offers around 20 grams of protein per bottle, supporting the maintenance of muscle mass, especially in geriatric or post-surgical patients.

On the official Fresubin pages, Fresenius Kabi highlights indications such as disease-related malnutrition, cancer, neurological conditions and conditions with increased energy needs. The drink is lactose-poor and gluten-free, making it suitable for many patients with common intolerances. Flavors like vanilla, cappuccino and fruits give clinicians options to better match individual preferences, which can matter when a patient hesitates at the first sip.

How Fresubin 2 kcal DRINK is used in practice

On a typical internal medicine ward in Germany, nurses often place a chilled Fresubin 2 kcal DRINK next to the morning coffee tray. Dietitians like Claudia Merker at Fresenius Kabi emphasize that splitting the bottle into several small servings over the day improves tolerance and intake. The recommended intake usually ranges from one to three bottles per day, depending on energy requirements and other food intake, always based on medical advice.

Because the product is classified as a food for special medical purposes, doctors and dietitians document the indication and monitor weight, lab values and clinical course. If a patient cannot manage enough oral intake despite the drink, the therapy may escalate to tube feeding, where Fresenius Kabi supplies enteral nutrition formulas as well. This layering of products shows how tightly Fresubin 2 kcal DRINK is integrated into broader malnutrition management pathways.

Market position inside the Fresubin family

Fresubin 2 kcal DRINK is one of several high-energy oral nutrition products under the Fresubin brand, which also includes Fresubin 1.5 kcal DRINK and disease-specific variants. Its clear positioning is "maximum calories in minimum volume", making it an attractive option when intake volume is the limiting factor. In regional markets like Germany, the product is widely listed by hospital pharmacies and outpatient homecare providers.

Analysts who follow Fresenius Kabi note that clinical nutrition, including products like Fresubin, contributes significantly to segment revenue and profitability within the group. Management around CEO Michael Sen has repeatedly underlined in conference calls that nutrition is a strategic pillar alongside IV drugs and infusion technology. For that strategy to work, products like Fresubin 2 kcal DRINK must hold or gain share in a competitive market with rivals such as Nestlé Health Science and Danone Nutricia.

Regulatory status and reimbursement

Fresubin 2 kcal DRINK is registered in the European Union as a food for special medical purposes and must be used under medical supervision, which places it in a specific regulatory niche between food and medicinal product. In Germany, oral nutrition supplements like Fresubin 2 kcal DRINK can be reimbursed by statutory health insurance under defined conditions, when prescribed by a physician for documented disease-related malnutrition.

This reimbursement framework directly affects volumes: if insurers tighten criteria or reduce reimbursement, hospitals and physicians may cut back on prescriptions. Conversely, growing awareness of malnutrition in hospitals and nursing homes can push demand higher. Fresenius Kabi therefore invests in clinical studies and educational programs to convince prescribers and payers of the clinical and economic benefits of early nutrition support.

Production, quality and sustainability aspects

Fresenius Kabi operates manufacturing sites in Europe that produce Fresubin oral nutrition, following quality standards such as ISO certifications and Good Manufacturing Practice principles. The company emphasizes stringent microbiological and nutrient content testing before batches leave the plant, because vulnerable patients rely on product safety.

On sustainability, Fresenius Kabi and the broader Fresenius group highlight initiatives to reduce CO? emissions and packaging waste. For products like Fresubin 2 kcal DRINK, this translates into efforts to optimize bottle materials, transport logistics and energy use at production sites. While investors increasingly scrutinize such ESG metrics, the immediate concern for clinicians remains that each bottle reliably delivers the declared calories and nutrients.

Why Fresubin 2 kcal DRINK matters for Fresenius

From a business angle, Fresubin 2 kcal DRINK sits at the intersection of demographic change and healthcare cost pressure. Aging populations mean more patients at risk of malnutrition, while hospitals search for relatively low-cost interventions that can shorten stays and reduce complications. Oral nutritional supplements like this one promise exactly that combination, making the category strategically interesting for Fresenius Kabi.

Fresenius has reported stable to growing sales in clinical nutrition in recent years, with Europe as a core market and expansion in Asia-Pacific and Latin America. Product lines like Fresubin 2 kcal DRINK contribute recurring, relatively predictable revenue, because many prescriptions run over weeks or months. On Xetra, the Fresenius SE & Co. KGaA share (ISIN DE0005785604) reflects expectations that these therapy areas will continue to support group earnings.